Astrazeneca's global oncology business Dato-DXd and lung cancer division head Lai Minglong has decided to leave
According to reporters, Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer division, has decided to leave the company to seek external development opportunities, with his last working day being June 30. AstraZeneca confirmed to reporters that the news is true. Public information shows that Lai Minglong joined AstraZeneca in June 2017 as Vice President of AstraZeneca China's Cardiovascular and Metabolism Business Unit and was promoted to General Manager of AstraZeneca China in 2018
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments